Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
06/2000
06/06/2000US6071961 For treating gastritis caused by caphylobacteria by administeing microbiocide comprising aliphatic or aromatic fatty acid, hydrotope and compatible acid
06/06/2000US6071956 Treatment of tissues to reduce subsequent response to injury
06/06/2000US6071952 Stabilized injectable pharmaceutical compositions containing taxoid anti-neoplastic agents
06/06/2000US6071942 Elevation of circulating blood histamine levels
06/06/2000US6071931 AT1 -receptor antagonists for preventing and treating postischemic renal failure and for protecting ischemic kidneys
06/06/2000US6071924 Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists
06/06/2000US6071918 A synergistic combination of at least one opioid antagonist, naltrexone, nalmefene; and at least one selective serotonin reuptake inhibitor paroxetine; side effect reduction
06/06/2000US6071914 Comparing the prolactin profile of a mammal to a standard prolactin profile for healthy mammals of the same species and sex and adjusting the prolactin profile of the afflicted mammal to conform to the standard; circadian rhythm rhythms
06/06/2000US6071896 Suppression of thromboxane levels by percutaneous administration of aspirin
06/06/2000US6071882 Administering an effective synergistic amount of leuteinizing hormone releasing hormone antagonist cetrorelix in combination with alpha-receptor blocking agents to treat the prostate hypertrophy and prostate cancer
06/06/2000US6071731 Enzymatic polypeptide for the attachment of histidine to transfer ribonucleic acid molecule; bactericides; wound healing agents
06/06/2000US6071722 Nucleic acids encoding a G-protein coupled 7TM receptor (AXOR-1)
06/06/2000US6071721 Calcium binding protein
06/06/2000US6071720 Polynucleotide coding a polypeptide associated with ionic mobility; for the diagnosis, treatment or prevention of nervous system disorders, cardiovascular disorders and cancer; anticarcinogenic agents
06/06/2000US6071541 Hydroxy acid or tannic acid or salt, hydrogen peroxide, and triclosan, clotrimazole, and/or farnesol; cleaning compounds; exfoliation
06/06/2000US6071538 Oral delivery composition comprising supramolecular complex
06/06/2000US6071516 Administering normal gamma-globulin
06/06/2000US6071514 Administering activated protein c and antiplatelet agent and/or anticoagulant
06/06/2000US6071509 Enhanced activation of natural killer cells using an NK cell activator and a hydrogen peroxide scavenger or inhibitor
06/06/2000US6071494 Lipid, protein or polymer and a gas or gaseous precursor, in combination with a renal vasodilator.
06/06/2000CA2130988C Pharmaceutical composition for treatment of sudden deafness
06/04/2000CA2291471A1 Lowering blood levels of lipoprotein(a)
06/02/2000WO2000031548A1 Prevention and treatment of amyloid-associated disorders
06/02/2000WO2000031532A1 Methods of identifying viral therapeutics
06/02/2000WO2000031291A1 Method for screening for substances which are activators, inhibitors or binders of pkb by the use of a substrate peptide and the use of the substrate peptide
06/02/2000WO2000031289A1 Use of activated trap for screening for specific inhibitor of trap and method for aiding in the identification of a compound for use in the treatment of diseases or degenerative conditions resulting in increased bone resorption
06/02/2000WO2000031273A2 Process for oxidising terpenes
06/02/2000WO2000031248A1 Humanized monoclonal antibodies
06/02/2000WO2000031238A2 Methods and reagents for increasing proliferative capacity and preventing replicative senescence
06/02/2000WO2000031135A1 TGF$G(b)1 INHIBITOR PEPTIDES
06/02/2000WO2000031133A2 Potassium channel interactors and uses therefor
06/02/2000WO2000031123A2 Retro-inversion peptides that target gastro-intestinal tract transport receptors and use thereof
06/02/2000WO2000031109A1 USE OF CORE 2 GlcNAc TRANSFERASE INHIBITORS IN TREATING INFLAMMATION
06/02/2000WO2000031085A1 Organophosphorous compounds and the use thereof
06/02/2000WO2000030715A1 Composition containing an analgesic and a xanthine or a xanthine derivative
06/02/2000WO2000030684A1 Medicinal compositions for periodic administration
06/02/2000WO2000030681A1 Antagonists of the alpha e beta 7 integrin as therapeutic agents for inflammatory diseases
06/02/2000WO2000030675A2 Medicinal product and method for treatment of conditions affecting neural stem cells or progenitor cells
06/02/2000WO2000030673A1 Uses for eph receptor antagonists and agonists to treat vascular disorders
06/02/2000WO2000030671A2 Nf-at mediates cardiac hypertrophy, methods and reagents related thereto
06/02/2000WO2000030665A1 Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of cardiovascular diseases
06/02/2000WO2000030664A1 Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of pulmonary diseases
06/02/2000WO2000030654A1 Anti-asthmatic combinations comprising surface active phospholipids
06/02/2000WO2000030649A1 Pharmaceutical compositions containing olanzapine-n-oxide
06/02/2000WO2000030648A1 2-hydroxymethylolanzapine compositions and methods
06/02/2000WO2000030635A1 Composition and use of rar antagonists for promoting chondrogenesis
06/02/2000WO2000030630A1 Combination products of a guanylate cyclase inhibitor and a local anesthetic for pain relief
06/02/2000WO2000030628A2 Method of inhibiting angiogenesis
06/02/2000WO2000030614A1 A process for producing particles with a converted amorphous and/or meta-stable crystalline region into crystalline state
06/02/2000WO2000030613A1 New process
06/02/2000WO2000030608A1 Pressurised metered dose inhalers (mdi)
06/02/2000WO2000030590A2 Methods and compositions for diagnosis and treatment of cancer based on the transcription factor ets2
06/02/2000WO2000030588A2 Treatment of hypertension
06/02/2000WO2000030587A2 NF-λB ACTIVATION INHIBITORS, AND THEIR PHARMACEUTICAL USES
06/02/2000WO2000030578A1 Enzymatic treatment and prevention of hypertrophic skin
06/02/2000WO2000030446A1 Dosage formulations for acetylcholinesterase inhibitors
06/02/2000WO2000018388A3 Antibiotic compositions for treatment of the eye, ear and nose
06/02/2000WO2000013703A9 Methods of treating hypertension and compositions for use therein
06/02/2000WO2000013650A3 Neuroprotection
06/02/2000WO2000012587A3 Polyamide chains of precise length, methods to manufacture them and their conjugates
06/02/2000WO2000010999A3 New compounds
06/02/2000WO2000010391A8 The use of adenosine a3 receptor antagonists to inhibit tumor growth
06/02/2000WO2000008177A3 Death associated kinase containing ankyrin repeats (dakar)
06/02/2000WO1999066075A3 Diagnostic method based on quantification of extramitochondrial dna
06/02/2000CA2698376A1 Pressurised metered dose inhalers (mdi)
06/02/2000CA2352963A1 Antagonists of the alpha e beta 7 integrin as therapeutic agents for inflammatory diseases
06/02/2000CA2352611A1 2-hydroxymethylolanzapine compositions and methods
06/02/2000CA2352599A1 Nf-at mediates cardiac hypertrophy, methods and reagents related thereto
06/02/2000CA2352585A1 Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of cardiovascular diseases
06/02/2000CA2352486A1 Methods and reagents for increasing proliferative capacity and preventing replicative senescence
06/02/2000CA2352461A1 Pharmaceutical composition for periodic administration
06/02/2000CA2352338A1 Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of pulmonary diseases
06/02/2000CA2352317A1 Amino alkylphosphonic acid derivatives and their use in treating infections
06/02/2000CA2352316A1 Treatment of hypertension
06/02/2000CA2351872A1 Use of activated trap for screening for specific inhibitor of trap and method for aiding in the identification of a compound for use in the treatment of diseases or degenerative conditions resulting in increased bone resorption
06/02/2000CA2351733A1 Nf-kb activation inhibitors, and their pharmaceutical uses
06/02/2000CA2351719A1 Pharmaceutical compositions containing olanzapine-n-oxide
06/02/2000CA2351365A1 Potassium channel interactors and uses therefor
06/02/2000CA2351347A1 Dosage formulations for acetylcholinesterase inhibitors
06/02/2000CA2351311A1 Uses for eph receptor antagonists and agonists to treat vascular disorders
06/02/2000CA2351166A1 Method for screening for substances which are activators, inhibitors or binders of pkb by the use of a substrate peptide and the use of the substrate peptide
06/02/2000CA2350599A1 Method of inhibiting angiogenesis
06/02/2000CA2349555A1 Composition and use of rar antagonists for promoting chondrogenesis
06/02/2000CA2349290A1 Retro-inversion peptides that target gastro-intestinal tract transport receptors and use thereof
06/02/2000CA2349229A1 Prevention and treatment of amyloid-associated disorders
06/02/2000CA2347940A1 Use of core 2 glcnac transferase inhibitors in treating inflammation
05/2000
05/31/2000EP1004590A2 Glucidic esters of branched carboxylic acids capable of inducing erythroid cellular differentiation
05/31/2000EP1004319A1 Remedies for solid tumor containing wilms' tumor gene (wt1) expression inhibitors
05/31/2000EP1004237A2 Method of introducing material into eggs during early embryonic development
05/31/2000EP1004022A1 Methods and compositions for overcoming resistance to biologic and chemotherapy
05/31/2000EP1003880A2 Human ubiquitin carrier protein e2-like protein and cyclin b-like protein
05/31/2000EP1003862A1 Human longevity-assurance protein homologs
05/31/2000EP1003858A1 New human growth regulator protein
05/31/2000EP1003856A1 Apaf-1, the ced-4 human homolog, an activator of caspase-3
05/31/2000EP1003844A1 Kinase activating dependent cyclin protein kinases, and their uses
05/31/2000EP1003787A2 Agent for the treatment and/or prophylaxis of microcirculation disorders
05/31/2000EP1003783A2 Lipoprotein-regulating medicaments
05/31/2000EP1003781A1 Interleukin-18 binding proteins, their preparation and use
05/31/2000EP1003780A1 Human f11 antigen: a cell surface receptor involved in platelet aggregation
05/31/2000EP1003767A1 Human tumor necrosis factor receptor tr10
1 ... 973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 ... 1151